Barclay Pearce Capital
- Dec 10, 2020
- 1 min read
Aegros developing COVID-19 hyperimmune solution
Our client Aegros is a biotech company focused on developing and delivering the best hyperimmunes to protect against existing and emerging diseases. Aegros has recently been featured in an article by STOCKHEAD.
The article opens with a captivating statement;
"Special Report: Sydney biotech company Aegros is making progress on a COVID-19 hyperimmune product made from the blood of recovering Covid patients – a treatment that’s badly needed, even with vaccines on the horizon."
What are hyperimmunes you ask?
"Hyperimmunes provide immediate protection to recipients, unlike vaccines whose protective effects take time to develop."
The article further highlights that Aegros' hyperimmune treatment is an important tool in combating COVID-19, since the effectiveness of vaccines in the real world remains unclear.
Aegros Managing Director, John Manusu says;
“It’s so critical to our country to protect our doctors and our nurses.”
With their focus on developing a hyperimmune solution for front-line healthcare workers, Aegros is on track to educate and prove that vaccines aren't the only solution for all COVID-19 scenarios.
Read the full STOCKHEAD announcement here.
Share Link